Medication info
Dapagliflozin Metformin Extended-Release Tablets 10/500 mg

Dapagliflozin Metformin Extended-Release Tablets 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
HK inno.N Co., Ltd.
Appearance
Pink, biconvex, oval-shaped film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202204037 · Approved 2022.11.08 · Insurance code 640007830

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of diabetes drug therapy who have inadequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience of diabetes drug therapy, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this drug have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because any change may cause a change in glycemic control, all changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and renal function is more likely to be decreased in elderly patients; therefore, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
HK inno.N Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control abnormalities
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication is used to enhance blood sugar control in adult patients with type 2 diabetes by complementing diet and exercise therapy. In particular, effective blood sugar management can be achieved through the combination of dapagliflozin and metformin. For patients with cardiovascular diseases or risk factors, it is important to refer to additional information provided by a specialist regarding the impact of this medication on the occurrence of cardiovascular events. Overall, this medication plays an important role in assisting blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of diabetes drug therapy who have inadequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience of diabetes drug therapy, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this drug have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because any change may cause a change in glycemic control, all changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and renal function is more likely to be decreased in elderly patients; therefore, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and helps in controlling blood sugar levels. However, it may rarely cause a serious side effect called lactic acidosis, so caution is needed. When used in combination with other diabetes medications, there may be an increased risk of hypoglycemia, requiring dosage adjustments. Patients with impaired kidney function, dehydration, severe infections, or weak heart function should not use this medication. It should also be discontinued for a certain period before and after surgeries or diagnostic tests involving radiopaque agents, and it should be resumed only after confirming normal kidney function. Pregnant or lactating women should not use this medication, and careful use is advised in children and elderly patients. While taking this medication, regular checks of blood sugar and kidney function are necessary, and patients should be vigilant for symptoms of hypoglycemia or dehydration. Additionally, genital or urinary infections may occur, so medical consultation is required immediately if such symptoms arise. This medication may lower vitamin B12 levels, so it is advisable to check vitamin B12 status during long-term use. Excessive alcohol should be avoided, and there is potential for drug interactions with other medications, so consultation with healthcare professionals is essential regarding co-medication. While taking this medication, fluid volume status and blood pressure should be periodically monitored, and caution should be exercised if dizziness or hypotensive symptoms occur. In case of overdose, immediate medical attention should be sought, and this medication should be kept out of reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis and related genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • reduced fluid volume
  • thirst
  • diabetic ketoacidosis
Show 83 more
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • reduced vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinopathy
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • swelling
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, avoid extremely hot or cold places, and store it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, biconvex, oval-shaped film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.